Different binding modes of structurally diverse ligands for human D3DAR

Journal of Chemical Information and Modeling

Volumn 50, Issue 12, 2010, Pages 2162-2175

  Ortore, Gabriella ^a   Tuccinardi, Tiziano ^a   Orlandini, Elisabetta ^a   Martinelli, Adriano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; BINDING ENERGY; LEAD COMPOUNDS; SCAFFOLDS;

BINDING MODES; COMPUTATIONAL STUDIES; DIFFERENT CLASS; LIGAND PROPERTIES; QUANTITATIVE CORRELATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP MODELING; RECEPTOR MODEL;

LIGANDS;

DOPAMINE 3 RECEPTOR; LIGAND;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER INTERFACE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCIBILITY;

DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, DOPAMINE D3; REPRODUCIBILITY OF RESULTS; USER-COMPUTER INTERFACE;

EID: 78650709104     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci100290f     Document Type: Article

References (96)

1. Visanji, N. P.; Fox, S. H.; Johnston, T.; Reyes, G.; Millan, M. J.; Brotchie, J. M. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease Neurobiol. Dis. 2009, 35, 184-92
2. Bezard, E.; Ferry, S.; Mach, U.; Stark, H.; Leriche, L.; Boraud, T.; Gross, C.; Sokoloff, P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function Nat. Med. 2003, 9, 762-7
3. Schwartz, J. C.; Diaz, J.; Pilon, C.; Sokoloff, P. Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions Brain Res. Rev. 2000, 31, 277-87
4. Heidbreder, C. A.; Newman, A. H. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders Ann. N.Y. Acad. Sci. 2010, 1187, 4-34
5. Pilla, M.; Perachon, S.; Sautel, F.; Garrido, F.; Mann, A.; Wermuth, C. G.; Schwartz, J. C.; Everitt, B. J.; Sokoloff, P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist Nature 1999, 400, 371-5
6. Hillefors-Berglund, M.; Von Euler, G. Pharmacology of dopamine D3 receptors in the islands of Calleja of the rat using quantitative receptor autoradiography Eur. J. Pharmacol. 1994, 261, 179-83
7. Sokoloff, P.; Giros, B.; Martres, M. P.; Andrieux, M.; Besancon, R.; Pilon, C.; Bouthenet, M. L.; Souil, E.; Schwartz, J. C. Localization and function of the D3 dopamine receptor Arzneimittelforschung 1992, 42, 224-30
8. Luedtkea, R. R.; Mach, R. H. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders Curr. Pharm. Des. 2003, 9, 643-71
9. Volkow, N. D.; Fowler, J. S.; Wang, G. J.; Swanson, J. M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications Mol. Psychiatry 2004, 9, 557-69
10. Platt, D. M.; Rowlett, J. K.; Spealman, R. D. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development Psychopharmacology 2002, 163, 265-82
11. Grabowski, J.; Shearer, J.; Merrill, J.; Negus, S. S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence Addict. Behav. 2004
12. Hackling, A. E.; Stark, H. Dopamine D3 receptor ligands with antagonist properties ChemBioChem 2002, 3, 946-61
13. Newman, A. H.; Grundt, P.; Nader, M. A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents J. Med. Chem. 2005, 48, 3663-79
14. Boeckler, F.; Gmeiner, P. Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity Biochim. Biophys. Acta 2007, 1768, 871-87
15. Boyfield, I.; Coldwell, M. C.; Hadley, M. S.; Johnson, C. N.; Riley, G. J.; Scott, E. E.; Stacey, R.; Stemp, G.; Thewlis, K. M. A novel series of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor Bioorg. Med. Chem. Lett. 1997, 7, 1995-1998 (Pubitemid 27338953)
16. Avenell, K. Y.; Boyfield, I.; Coldwell, M. C.; Hadley, M. S.; Healy, M. A.; Jeffrey, P. M.; Johnson, C. N.; Nash, D. J.; Riley, G. J.; Scott, E. E.; Smith, S. A.; Stacey, R.; Stemp, G.; Thewlis, K. M. Fused aminotetralins: novel antagonists with high selectivity for the dopamine D3 receptor Bioorg. Med. Chem. Lett. 1998, 8, 2859-64
17. Avenell, K. Y.; Boyfield, I.; Hadley, M. S.; Johnson, C. N.; Nash, D. J.; Riley, G. J.; Stemp, G. Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor Bioorg. Med. Chem. Lett. 1999, 9, 2715-20
18. Stemp, G.; Ashmeade, T.; Branch, C. L.; Hadley, M. S.; Hunter, A. J.; Johnson, C. N.; Nash, D. J.; Thewlis, K. M.; Vong, A. K.; Austin, N. E.; Jeffrey, P.; Avenell, K. Y.; Boyfield, I.; Hagan, J. J.; Middlemiss, D. N.; Reavill, C.; Riley, G. J.; Routledge, C.; Wood, M. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4- quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat J. Med. Chem. 2000, 43, 1878-85
19. Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Coldwell, M. C.; Hadley, M. S.; Jeffrey, P.; Johns, A.; Johnson, C. N.; Nash, D. J.; Riley, G. J.; Smith, S. A.; Stacey, R. C.; Stemp, G.; Thewlis, K. M.; Vong, A. K. Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor Bioorg. Med. Chem. Lett. 1999, 9, 179-84
20. Micheli, F.; Bonanomi, G.; Braggio, S.; Capelli, A. M.; Damiani, F.; Di Fabio, R.; Donati, D.; Gentile, G.; Hamprecht, D.; Perini, O.; Petrone, M.; Tedesco, G.; Terreni, S.; Worby, A.; Heidbreder, C. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems Bioorg. Med. Chem. Lett. 2008, 18, 908-12
21. Micheli, F.; Bonanomi, G.; Blaney, F. E.; Braggio, S.; Capelli, A. M.; Checchia, A.; Curcuruto, O.; Damiani, F.; Fabio, R. D.; Donati, D.; Gentile, G.; Gribble, A.; Hamprecht, D.; Tedesco, G.; Terreni, S.; Tarsi, L.; Lightfoot, A.; Stemp, G.; Macdonald, G.; Smith, A.; Pecoraro, M.; Petrone, M.; Perini, O.; Piner, J.; Rossi, T.; Worby, A.; Pilla, M.; Valerio, E.; Griffante, C.; Mugnaini, M.; Wood, M.; Scott, C.; Andreoli, M.; Lacroix, L.; Schwarz, A.; Gozzi, A.; Bifone, A.; Ashby, C. R., Jr.; Hagan, J. J.; Heidbreder, C. 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists J. Med. Chem. 2007, 50, 5076-89
22. Macdonald, G. J.; Branch, C. L.; Hadley, M. S.; Johnson, C. N.; Nash, D. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K.; Austin, N. E.; Jeffrey, P.; Winborn, K. Y.; Boyfield, I.; Hagan, J. J.; Middlemiss, D. N.; Reavill, C.; Riley, G. J.; Watson, J. M.; Wood, M.; Parker, S. G.; Ashby Jr, C. R. Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist J. Med. Chem. 2003, 46, 4952-64
23. Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Hadley, M. S.; Jeffrey, P.; Johnson, C. N.; Macdonald, G. J.; Nash, D. J.; Riley, G. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K.; Wood, M. Novel 2,3,4,5-tetrahydro-1H-3-benzazepines with high affinity and selectivity for the dopamine D3 receptor Bioorg. Med. Chem. Lett. 2000, 10, 2553-5
24. Haadsma-Svensson, S. R.; Cleek, K. A.; Dinh, D. M.; Duncan, J. N.; Haber, C. L.; Huff, R. M.; Lajiness, M. E.; Nichols, N. F.; Smith, M. W.; Svensson, K. A.; Zaya, M. J.; Carlsson, A.; Lin, C. H. Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans J. Med. Chem. 2001, 44, 4716-32
25. Sautel, F.; Griffon, N.; Sokoloff, P.; Schwartz, J. C.; Launay, C.; Simon, P.; Costentin, J.; Schoenfelder, A.; Garrido, F.; Mann, A. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents J. Pharmacol. Exp. Ther. 1995, 275, 1239-46
26. Dubuffet, T.; Newman-Tancredi, A.; Cussac, D.; Audinot, V.; Loutz, A.; Millan, M. J.; Lavielle, G. Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist Bioorg. Med. Chem. Lett. 1999, 9, 2059-64
27. Hackling, A.; Ghosh, R.; Perachon, S.; Mann, A.; Holtje, H. D.; Wermuth, C. G.; Schwartz, J. C.; Sippl, W.; Sokoloff, P.; Stark, H. N-(omega-(4-(2- methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands J. Med. Chem. 2003, 46, 3883-99
28. Boeckler, F.; Lanig, H.; Gmeiner, P. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes J. Med. Chem. 2005, 48, 694-709
29. Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Levant, B.; Wang, S. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach J. Med. Chem. 2003, 46, 4377-92
30. Ding, K.; Chen, J.; Ji, M.; Wu, X.; Varady, J.; Yang, C. Y.; Lu, Y.; Deschamps, J. R.; Levant, B.; Wang, S. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands J. Med. Chem. 2005, 48, 3171-81
31. Micheli, F.; Bonanomi, G.; Braggio, S.; Capelli, A. M.; Celestini, P.; Damiani, F.; Di Fabio, R.; Donati, D.; Gagliardi, S.; Gentile, G.; Hamprecht, D.; Petrone, M.; Radaelli, S.; Tedesco, G.; Terreni, S.; Worby, A.; Heidbreder, C. New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems Bioorg. Med. Chem. Lett. 2008, 18, 901-7
32. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor Science 2000, 289, 739-745
33. Ivanov, A. A.; Barak, D.; Jacobson, K. A. Evaluation of Homology Modeling of G Protein-Coupled Receptors in Light of the A2A Adenosine Receptor Crystallographic Structure J. Med. Chem. 2009, 52, 3284-3292
34. Mustafi, D.; Palczewski, K. Topology of Class A G Protein-Coupled Receptors: Insights Gained from Crystal Structures of Rhodopsins, Adrenergic and Adenosine Receptors Mol. Pharmacol. 2009, 75, 1-12
35. Dal Ben, D.; Lambertucci, C.; Marucci, G.; Volpini, R.; Cristalli, G. Adenosine receptor modeling: what does the A2A crystal structure tell us Curr. Top. Med. Chem. 2010, 10, 993-1018
36. Simossis, V. A.; Heringa, J. PRALINE: a multiple sequence alignment toolbox that integrates homology-extended and secondary structure information Nucleic Acids Res. 2005, 33, W289-W294 Web Server issue
37. Ortore, G.; Tuccinardi, T.; Bertini, S.; Martinelli, A. A theoretical study to investigate D2DAR/D4DAR selectivity: receptor modeling and molecular docking of dopaminergic ligands J. Med. Chem. 2006, 49, 1397-1407
38. Robinson, S. W.; Jarvie, K. R.; Caron, M. G. High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains Mol. Pharmacol. 1994, 46, 352-6
39. Fiser, A.; Do, R. K.; Sali, A. Modeling of loops in protein structures Protein Sci. 2000, 9, 1753-1773
40. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thorton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 1993, 26, 283-291
41. Case, D. A.; Darden, T. A.; Cheatham, T. E. I.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. AMBER 8; University of California, San Francisco, CA, 2004.
42. Martinelli, A.; Tuccinardi, T. GPCR modeling: methods and validation. An overview of recent developments Expert Opin. Drug Discovery 2006, 1, 459-476
43. Javitch, J. A.; Fu, D.; Chen, J.; Karlin, A. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method Neuron 1995, 14, 825-831
44. Javitch, J. A.; Fu, D.; Chen, J. Residues in the Fifth Membrane-Spanning Segment of the Dopamine D2 Receptor Exposed in the Binding-Site Crevice Biochemistry 1995, 34, 16433-16439
45. Fu, D.; Ballesteros, J. A.; Weinstein, H.; Chen, J.; Javitch, J. A. Residues in the Seventh Membrane-Spanning Segment of the Dopamine D2 Receptor Accessible in the Binding-Site Crevice Biochemistry 1996, 35, 11278-11285
46. Javitch, J. A.; Ballesteros, J. A.; Weinstein, H.; Chen, J. A Cluster of Aromatic Residues in the Sixth Membrane-Spanning Segment of the Dopamine D2 Receptor Is Accessible in the Binding-Site Crevice Biochemistry 1998, 37, 998-1006
47. Javitch, J. A.; Ballesteros, J. A.; Chen, J.; Chiappa, V.; Simpson, M. M. Electrostatic and Aromatic Microdomains within the Binding-Site Crevice of the D2 Receptor: Contributions of the Second Membrane-Spanning Segment Biochemistry 1999, 38, 7961-7968
48. Javitch, J. A.; Shi, L.; Simpson, M. M.; Chen, J.; Chiappa, V.; Visiers, I.; Weinstein, H.; Ballesteros, J. A. The Fourth Transmembrane Segment of the Dopamine D2 Receptor: Accessibility in the Binding-Site Crevice and Position in the Transmembrane Bundl Biochemistry 2000, 39, 12190-12199
49. Shi, L.; Simpson, M. M.; Ballesteros, J. A.; Javitch, J. A. The First Transmembrane Segment of the Dopamine D2 Receptor: Accessibility in the Binding-Site Crevice and Position in the Transmembrane Bundle Biochemistry 2001, 40, 12339-12348
50. Shi, L.; Javitch, J. A. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 440-445
51. Mansour, A.; Meng, F.; Meador-Woodruff, J. H.; P., T. L.; Civelli, O.; Akil, H. Site-Directed Mutagenesis of the Human Dopamine D2 Receptor Eur. J. Pharmacol. 1992, 227, 205-214
52. Cox, B. A.; Henningsen, R. A.; Spanoyannis, A.; Neve, R. L.; Neve, K. A. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors J. Neurochem. 1992, 59, 627-635
53. Cho, W.; Mansour, A.; Taylor, L. P. Hydrophobic Residues of the D2 Dopamine Receptor Are Important for Binding and Signal Transduction J. Neurochem. 1995, 65, 2105-2115
54. Woodward, R.; Coley, C.; Daniell, S.; Naylor, L. H.; Strange, P. G. Investigation of the role of conserved serine residues in the long form of the rat D2 dopamine receptor using site-directed mutagenesis J. Neurochem. 1996, 66, 394-402
55. Wiens, B. L.; Nelson, C. S.; Neve, K. A. Contribution of serine residues to constitutive and agonist-induced signalling via the D2s dopamine receptor: evidence for multiple, agonist-specific active conformations Mol. Pharmacol. 1998, 54, 435-444
56. Coley, C.; Woodward, R.; Johansson, A. M.; Strange, P. G.; Naylor, L. H. Effect of multiple serine/alanine mutations in the transmembrane spanning region V of the D2 dopamine receptor on ligand binding J. Neurochem. 2000, 74, 358-366
57. Shi, L.; Javitch, J. A. The binding site of aminergic G proteincoupled receptors: the transmembrane segments and second extracellular loop Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467
58. Ballesteros, J. A.; Shi, L.; Javitch, J. A. Structural mimicry in G protein-coupled receptors: implications of the high-resolution of rhodopsin for structure-function analysis of rhodopsin-like receptors Mol. Pharmacol. 2001, 60, 1-19
59. Sartania, N.; Strange, P. G. Role of conserved serine residues in the interaction of agonists with D3 dopamine receptors J. Neurochem. 1999, 72, 2621-4
60. Tuccinardi, T.; Ortore, G.; Manera, C.; Saccomanni, G.; Martinelli, A. Adenosine receptor modelling. A1/A2a selectivity Eur. J. Med. Chem. 2006, 41, 321-329
61. Shi, L.; Liapakis, G.; Xu, R.; Guarnieri, F.; Ballesteros, J. A.; Javitch, J. A. β2 Adrenergic Receptor Activation: Modulation of the Proline Kink in Transmembrane 6 by a Rotamer Toggle Switch J. Biol. Chem. 2002, 277, 40989-40996
62. Lundstrom, K.; Turpin, M. P.; Large, C.; Robertson, G.; Thomas, P.; Lewell, X. Q. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system J. Recept. Signal Transduction Res. 1998, 18, 133-50
63. Alberts, G. L.; Pregenzer, J. F.; Im, W. B. Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras Mol. Pharmacol. 1998, 54, 379-88
64. Bettinetti, L.; Schlotter, K.; Hubner, H.; Gmeiner, P. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists J. Med. Chem. 2002, 45, 4594-7
65. Ehrlich, K.; Gotz, A.; Bollinger, S.; Tschammer, N.; Bettinetti, L.; Harterich, S.; Hubner, H.; Lanig, H.; Gmeiner, P. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding J. Med. Chem. 2009, 52, 4923-35
66. Cha, M. Y.; Lee, I. Y.; Cha, J. H.; Choi, K. I.; Cho, Y. S.; Koh, H. Y.; Pae, A. N. QSAR studies on piperazinylalkylisoxazole analogues selectively acting on dopamine D3 receptor by HQSAR and CoMFA Bioorg. Med. Chem. 2003, 11, 1293-8
67. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. J. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
68. Chivers, J. K.; Gommeren, W.; Leysen, J. E.; Jenner, P.; Marsden, C. D. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors J. Pharm. Pharmacol. 1988, 40, 415-421
69. Millan, M. J.; Audinot, V.; Rivet, J. M.; Gobert, A.; Vian, J.; Prost, J. F.; Spedding, M.; Peglion, J. L. S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats Eur. J. Pharmacol. 1994, 260, R3-5
70. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics Nature 1990, 347, 146-51
71. Peglion, J. L.; Vian, J.; Goument, B.; Despaux, N.; Audinot, V.; Millan, M. J. Tetracyclic analogues of [+]-S 14297: Synthesis and determination of affinity and selectivity at cloned human dopamine D3 vs D2 receptors Bioorg. Med. Chem. Lett. 1997, 7, 881-886
72. Zhao, Y.; L., X.; Yang, C.; Huang, Z.; Fu, W.; Hou, T.; Zhang, J. Computational Modeling Toward Understanding Agonist Binding on Dopamine 3 J. Chem. Inf. Model. 2010, 50, 1633-1643
73. Hobrath, J. V.; Wang, S. Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling J. Med. Chem. 2006, 49, 4470-6
74. Nilsson, J.; Wikstrom, H.; Smilde, A.; Glase, S.; Pugsley, T.; Cruciani, G.; Pastor, M.; Clementi, S. GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype J. Med. Chem. 1997, 40, 833-40
75. GOLPE, version 4.5; Multivariate Infometric Analysis Srl.: Perugia, Italy, 1999.
76. Tuccinardi, T. Docking-Based Virtual Screening: Recent Developments Comb. Chem. High Throughput Screen. 2009, 12, 303-314
77. NCI/DTP Open Chemical Repository; National Cancer Institute: Bethesda, MD; http://dtp.cancer.gov/ (Accessed 03/15/10).
78. Heidler, P.; Zohrabi-Kalantari, V.; Calmels, T.; Capet, M.; Berrebi-Bertrand, I.; Schwartz, J. C.; Stark, H.; Link, A. Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin- 1-yl]butyl}carboxamides Bioorg. Med. Chem. 2005, 13, 2009-14
79. Leopoldo, M.; Lacivita, E.; Colabufo, N. A.; Contino, M.; Berardi, F.; Perrone, R. First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure J. Med. Chem. 2005, 48, 7919-22
80. Wustrow, D.; Belliotti, T.; Glase, S.; Kesten, S. R.; Johnson, D.; Colbry, N.; Rubin, R.; Blackburn, A.; Akunne, H.; Corbin, A.; Davis, M. D.; Georgic, L.; Whetzel, S.; Zoski, K.; Heffner, T.; Pugsley, T.; Wise, L. Aminopyrimidines with high affinity for both serotonin and dopamine receptors J. Med. Chem. 1998, 41, 760-71
81. Boeckler, F.; Gmeiner, P. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects Pharmacol. Ther. 2006, 112, 281-333
82. Belliotti, T. R.; Kesten, S. R.; Wustrow, D. J.; Georgic, L. M.; Zoski, K. T.; Akunne, H. C.; Wise, L. D. Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligands Bioorg. Med. Chem. Lett. 1997, 7, 2403-2408
83. Murray, A. M.; Hyde, T. M.; Knable, M. B.; Herman, M. M.; Bigelow, L. B.; Carter, J. M.; Weinberger, D. R.; Kleinman, J. E. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia J. Neurosci. 1995, 15, 2186-91
84. Gasteiger, E.; Gattiker, A.; Hoogland, C.; Ivanyi, I.; Appel, R. D.; Bairoch, A. ExPASy: the proteomics server for in-depth protein knowledge and analysis Nucleic Acids Res. 2003, 31, 3784-3788
85. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G-protein-coupled receptor Science 2000, 289, 739-745
86. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; P.E., B. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242
87. McGuffin, L. J.; Bryson, K.; Jones, D. T. The PSIPRED protein structure prediction server Bioinformatics 2000, 16, 404-405
88. Ballesteros, J. A.; Weinstein, H. W. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors Methods Neurosci. 1995, 25, 366-428
89. Tuccinardi, T.; Calderone, V.; Rapposelli, S.; Martinelli, A. Proposal of a New Binding Orientation for Non-Peptide AT1 Antagonists: Homology Modeling, Docking and Three-Dimensional Quantitative Structure-Activity Relationship Analysis J. Med. Chem. 2006, 49, 4305-4316
90. Jakalian, A.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation J. Comput. Chem. 2002, 23, 1623-1641
91. Maestro, version 7.5; Schrödinger Inc.: Portland, OR, 1999.
92. Macromodel, version 8.5; Schrodinger Inc.: Portland, OR, 1999.
93. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857
94. Tuccinardi, T.; Ortore, G.; Rossello, A.; Supuran, C. T.; Martinelli, A. Homology Modeling and Receptor-Based 3D-QSAR Study of Carbonic Anhydrase IX J. Chem. Inf. Model. 2007, 47, 2253-2262 (Pubitemid 350275090)
95. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
96. Freedman, S. B.; Patel, S.; Marwood, R.; Emms, F.; Seabrook, G. R.; Knowles, M. R.; McAllister, G. Expression and pharmacological characterization of the human D3 dopamine receptor J. Pharmacol. Exp. Ther. 1994, 268, 417-426